GP
REGN icon

GLR Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

GLR Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$218K Hold
350
– – 0.1% 109
2026
Q1 		$270K Buy
+350
New +$268K 0.15% 87

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

GLR Partners's REGN Position: Q2 2026 in Review

GLR Partners held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 350 shares worth $218K. The position accounts for 0.1% of the portfolio, ranked #109.

GLR Partners first reported a position in REGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $270K in Q1 2026. 1,327 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • GLR Partners held 350 shares of Regeneron Pharmaceuticals worth $218K as of Q2 2026.
  • GLR Partners left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.1% of GLR Partners's portfolio in Q2 2026, its #109 holding.
  • GLR Partners first reported a position in Regeneron Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • GLR Partners's Regeneron Pharmaceuticals position peaked at $270K in Q1 2026.
  • 1,327 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on GLR Partners's 13F filing for Q2 2026, filed 27 Jul 2026.